Additionally, our findings reveal that prioritized DESs with predicted functional damage in non-related cancer genes (according to the CGC) could be involved in drug response, such as Chr17:33430313 (T/C) in RAD51D, a gene involved in DDR and homologous recombination (HR), with a E253G change identified in our study, which has been reported in ovarian and breast cancer patients. The gene discussed is RAD51D; the disease is breast cancer.